Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL

Leukemia and Lymphoma

Volumn 49, Issue 11, 2008, Pages 2108-2115

  Morilla, Alison ^a   Gonzalez de Castro, David ^a   Del Giudice, Ilaria ^a   Osuji, Nnenna ^a   Else, Monica ^a   Morilla, Ricardo ^a   Brito Babapulle, Vasantha ^a   Rudenko, Hannah ^a   Matutes, Estella ^a   Dearden, Claire ^a   Catovsky, Daniel ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CD38; CLL; IGHV mutations; Treatment free interval; ZAP 70

Indexed keywords

CD38 ANTIGEN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; BIOLOGICAL MARKERS; FEMALE; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 57049115898     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802360810     Document Type: Article

References (29)

1. Kipps, T. J. (2000) Chronic lymphocytic leukemia. Curr Opin Hematol, 7, pp. 223-234.
2. Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G. Dohner, H. et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood, 111, pp. 5446-5456.
3. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. and Stevenson, F. K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, pp. 1848-1854.
4. Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A. Allen, S. L. et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, pp. 1840-1847.
5. Tobin, G., Thunberg, U., Johnson, A., Eriksson, I., Soderberg, O. Karlsson, K. et al. (2003) Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: Implicating recognition of a common antigen epitope. Blood, 101, pp. 4952-4957.
6. Tobin, G., Thunberg, U., Johnson, A., Thorn, I., Soderberg, O. Hultdin, M. et al. (2002) Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood, 99, pp. 2262-2264.
7. Isakov, N., Wange, R. L., Burgess, W. H., Watts, J. D., Aebersold, R. and Samelson, L. E. (1995) ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity. J Exper Med, 181, pp. 375-380.
8. Wiestner, A., Rosenwald, A., Barry, T. S., Wright, G., Davis, R. E. Henrickson, S. E. et al. (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood, 101, pp. 4944-4951.
9. Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E. Yu, X. et al. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exper Med, 194, pp. 1639-1647.
10. Chen, L., Apgar, J., Huynh, L., Dicker, F., Giago-McGahan, T. Rassenti, L. et al. (2005) ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood, 105, pp. 2036-2041.
11. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D. Rozman, M. et al. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New Engl J Med, 348, pp. 1764-1775.
12. Orchard, J. A., Ibbotson, R. E., Davis, Z., Wiestner, A., Rosenwald, A. Thomas, P. W. et al. (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet, 363, pp. 105-111.
13. Rassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J. Gribben, J. G. et al. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. New Engl J Med, 351, pp. 893-901.
14. Del Principe, M I, Del Poeta, G, Buccisano, F., Maurillo, L., Venditti, A. Zucchetto, A. et al. (2006) Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood, 108, pp. 853-861.
15. Deaglio, S., Capobianco, A., Bergui, L., Durig, J., Morabito, F. Duhrsen, U. et al. (2003) CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood, 102, pp. 2146-2155.
16. Hamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z., Thomas, P. W. Stevenson, F. K. et al. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood, 99, pp. 1023-1029.
17. Del Giudice, I, Morilla, A., Osuji, N., Matutes, E., Morilla, R. Burford, A. et al. (2005) Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer, 104, pp. 2124-2132.
18. Schroers, R., Griesinger, F., Trumper, L., Haase, D., Kulle, B. Klein-Hitpass, L. et al. (2005) Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia, 19, pp. 750-758.
19. Hus, I., Podhorecka, M., Bojarska-Junak, A., Rolinski, J., Schmitt, M. Sieklucka, M. et al. (2006) The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol, 17, pp. 683-690.
20. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M. J. Bezares, R. F. et al. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet, 370, pp. 230-239.
21. Thornton, P. D., Fernandez, C., Giustolisi, G. M., Morilla, R., Atkinson, S. A'Hern, R. P. et al. (2004) CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J, 5, pp. 145-151.
22. Krober, A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E. Lichter, P. et al. (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100, pp. 1410-1416.
23. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A. Bullinger, L. et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New Engl J Med, 343, pp. 1910-1916.
24. van Dongen, J. J., Langerak, A. W., Bruggemann, M., Evans, P. A., Hummel, M. Lavender, F. L. et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 17, pp. 2257-2317.
25. Lefranc, M. P. (2001) IMGT, the international ImMunoGeneTics database. Nucleic Acids Res, 29, pp. 207-209.
26. Zupo, S., Isnardi, L., Megna, M., Massara, R., Malavasi, F. Dono, M. et al. (1996) CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood, 88, pp. 1365-1374.
27. Ghia, P., Guida, G., Scielzo, C., Geuna, M. and Caligaris-Cappio, F. (2004) CD38 modifications in chronic lymphocytic leukemia: Are they relevant?. Leukemia, 18, pp. 1733-1735.
28. Hayat, A., O'Brien, D., O'Rourke, P., McGuckin, S., Fitzgerald, T. Conneally, E. et al. (2006) CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma, 47, pp. 2371-2379.
29. Krober, A., Bloehdorn, J., Hafner, S., Buhler, A., Seiler, T. Kienle, D. et al. (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol, 24, pp. 969-975.